1.17
5.88%
0.065
プレマーケット:
1.13
-0.04
-3.42%
Rallybio Corp (RLYB) 最新ニュース
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com India
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan
Rallybio reveals higher FNAIT risk across populations - Investing.com
Rallybio reveals higher FNAIT risk across populations - Investing.com India
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - StockTitan
Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Rallybio announces board member resignation - Investing.com
Rallybio announces board member resignation - Investing.com India
Rallybio announces board member resignation By Investing.com - Investing.com UK
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks
Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - StockTitan
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
Rallybio - FiercePharma
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - StockTitan
Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St
Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times
Rallybio to Present at Upcoming Investor Conferences - Business Wire
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia
HC Wainwright Comments on Rallybio Co.’s Q3 2024 Earnings (NASDAQ:RLYB) - Defense World
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com UK
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Australia
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com Australia
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com India
Rallybio (NASDAQ:RLYB) PT Lowered to $6.00 - Defense World
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com UK
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth? - Yahoo Finance
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Rallybio stock plunges to 52-week low at $1.12 amid market challenges - Investing.com
31,294 Shares in Rallybio Co. (NASDAQ:RLYB) Bought by Acadian Asset Management LLC - Defense World
Brokerages Set Rallybio Co. (NASDAQ:RLYB) Target Price at $12.20 - MarketBeat
Rallybio co-founder joins another CT bioscience company board - Hartford Business Journal
Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors - StockTitan
Rallybio Co. (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio co-founder to step down as executive chairman, leave full-time role - Hartford Business Journal
Rallybio Corp announces executive transition plan - Investing.com
Rallybio Executive Chairman Announces Plans to Step Down - TipRanks
Short Interest in Rallybio Co. (NASDAQ:RLYB) Drops By 16.9% - MarketBeat
Rallybio Co. (NASDAQ:RLYB) Short Interest Down 16.9% in June - Defense World
Rallybio Co. (NASDAQ:RLYB) Short Interest Down 16.9% in June - American Banking and Market News
Rallybio Reports First Quarter 2023 Financial Results - Quantisnow
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit - Business Wire
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit - Winchester Herald Chronicle
Rallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Rallybio Co. (NASDAQ:RLYB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Rallybio Corp Inc. (RLYB) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Was anything negative for Rallybio Corp (RLYB) stock last session? – US Post News - US Post News
大文字化:
|
ボリューム (24 時間):